KB Home to Release 2025 Second Quarter Earnings on
LOS ANGELES--(BUSINESS WIRE)--KB Home (NYSE: KBH) today announced that it will release earnings for its second quarter ended May 31, 2025 after the market closes on Monday, June 23, 2025. A live webcast of the Company's earnings conference call will be held the same day at 2:00 p.m. Pacific Time, 5:00 p.m. Eastern Time.
To listen to the call, go to the Investor Relations section of the KB Home website at investor.kbhome.com and select the Second Quarter Earnings Conference Call link in the Events and Presentations section. The webcast will be available for replay at the KB Home website for 30 days.
About KB Home
KB Home is one of the largest and most trusted homebuilders in the United States. We operate in 49 markets, have built nearly 700,000 quality homes in our more than 65-year history, and are honored to be the #1 customer-ranked national homebuilder based on third-party buyer surveys. What sets KB Home apart is building strong, personal relationships with every customer and creating an exceptional homebuying experience that offers our homebuyers the ability to personalize their home based on what they value at a price they can afford. As the industry leader in sustainability, KB Home has achieved one of the highest residential energy-efficiency ratings and delivered more ENERGY STAR® certified homes than any other builder, helping to lower the total cost of homeownership. For more information, visit kbhome.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
IQVIA Holdings (NYSE:IQV) Sees 11% Share Price Rise Over Last Week
IQVIA Holdings experienced a 10% rise in share price over the last week, correlating with its recent developments, notably the dosing of the first patient in the RENEW Phase 2 trial and its strategic alliance with Sarah Cannon Research Institute to optimize oncology trials. These initiatives likely provided a positive sentiment boost, aligning well with the broader market momentum, as indices such as the S&P 500 also reached new highs. The market's anticipation over US-China trade talks and overall strong corporate earnings have supported the upward trend, further enhancing IQV's market performance. We've identified 1 warning sign for IQVIA Holdings that you should be aware of. Uncover 18 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. The recent 10% rise in IQVIA Holdings' share price has been influenced by important developments like the dosing in the RENEW Phase 2 trial and a key alliance with Sarah Cannon Research Institute. These initiatives are expected to potentially drive revenue growth, particularly as the strategic alliance optimizes oncology trials. The company's past performance, with total returns of 10.45% over five years, suggests modest growth in investor value. However, compared to the US Life Sciences industry's one-year return of 27% decline, IQVIA's recent rise highlights positive market sentiment. These initiatives, combined with FDA reforms and NVIDIA collaboration, may lower operational costs and have a favorable impact on earnings forecasts. Analysts predict revenue to grow by 5.2% annually over the next three years, which is somewhat cautious compared to the general expectations for the life sciences sector. The recent share price movement to US$146.2 remains below the consensus price target of US$216.31, indicating potential for future appreciation if the projected growth in revenue and earnings materializes. Click here to discover the nuances of IQVIA Holdings with our detailed analytical financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:IQV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Applied Medical Technology, Inc. Unveils Redesigned Mobile App Aligned with Recent Website Refresh
BRECKSVILLE, Ohio., June 10, 2025 /PRNewswire/ -- Applied Medical Technology, Inc. (AMT), a leader in innovative medical devices, is proud to announce the launch of its redesigned mobile application, AMT ONE Source®. This strategic update follows a successful website redesign completed late 2024, ensuring that both platforms now offer a cohesive, user-friendly digital experience. Enhancing User Experience Across PlatformsThe redesigned mobile app mirrors the modern, intuitive design language introduced during the website refresh. With a renewed focus on user experience and engagement, the mobile platform now features streamlined interfaces and updated information. "In today's fast-paced healthcare environment, it is essential that our digital platforms are not only reliable but also easy to navigate and visually appealing," said Bill Bentley, National Sales Manager. "Created with our youngest patients in mind, the redesign was thoughtfully developed to be more engaging, age-appropriate, and easy to navigate—helping children and their families feel more supported and empowered throughout their healthcare journey." Key Features and Benefits Unified Design Aesthetic: The mobile app adopts the clean, modern design previously launched on the website, providing a consistent look and feel across all digital touchpoints. Richer Content Experience: The app now features an expanded content database, providing a broader range of resources and information to support users with timely, relevant, and easy-to-access content. Improved Performance: The redesigned app features enhanced performance, with a new backend architecture that allows for faster content updates, easier maintenance, and more frequent improvements to keep the experience fresh and relevant. AMT partnered with Cleveland-Ohio based software company, Stream 9, on the redesign. Their strong track record in software design and development brought deep technical expertise and a strategic approach. "We're fortunate in our business to develop custom software projects for businesses of all kinds; but it's especially rewarding to work on a project that will deliver such a direct benefit to patients and their caregivers. AMT brought a clear vision to the table, and we worked closely together to translate that into a modern, scalable, and user-friendly digital experience," shared Kirk Miesle, Founder of Stream 9. The AMT ONE Source® app is available now on the App Store and Google Play. About AMT: Applied Medical Technology, Inc. (AMT) is a global leader in enteral and surgical devices committed to improving lives through innovation. For 40 years, AMT has bridged the gap between medical technology and patient needs, collaborating with healthcare professionals and users to develop high-quality, life-enhancing solutions. Our holistic approach prioritizes the well-being of the whole person, not just the device they use. View original content to download multimedia: SOURCE Applied Medical Technology, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
21 minutes ago
- Business Wire
KBRA Assigns Preliminary Ratings to EFMT 2025-NQM2
NEW YORK--(BUSINESS WIRE)--KBRA assigns preliminary ratings to seven classes of mortgage pass-through certificates from EFMT 2025-NQM2, a $282.8 million non-prime RMBS transaction. The underlying collateral, comprising 656 residential mortgages, is characterized by a notable concentration of alternative income documentation, with 83.9% of the loans underwritten using bank statements, DSCR, and asset underwriting documentation types. The majority of loans are either classified as non-qualified mortgages (56.9%) or exempt (40.1%) from the Ability-to-Repay/Qualified Mortgage rule due to being originated for non-consumer loan purposes. LendSure Mortgage Corp. (LendSure), an affiliated originator of Ellington Management Group ('Ellington') originated 36.6% of the pool. KBRA's rating approach incorporated loan-level analysis of the mortgage pool through its Residential Asset Loss Model (REALM), an examination of the results from third-party loan file due diligence, cash flow modeling analysis of the transaction's payment structure, reviews of key transaction parties and an assessment of the transaction's legal structure and documentation. This analysis is further described in our U.S. RMBS Rating Methodology. To access ratings and relevant documents, click here. Click here to view the report. Related Publications Methodologies Disclosures Further information on key credit considerations, sensitivity analyses that consider what factors can affect these credit ratings and how they could lead to an upgrade or a downgrade, and ESG factors (where they are a key driver behind the change to the credit rating or rating outlook) can be found in the full rating report referenced above. A description of all substantially material sources that were used to prepare the credit rating and information on the methodology(ies) (inclusive of any material models and sensitivity analyses of the relevant key rating assumptions, as applicable) used in determining the credit rating is available in the Information Disclosure Form(s) located here. Information on the meaning of each rating category can be located here. Further disclosures relating to this rating action are available in the Information Disclosure Form(s) referenced above. Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at About KBRA Kroll Bond Rating Agency, LLC (KBRA), one of the major credit rating agencies (CRA), is a full-service CRA registered with the U.S. Securities and Exchange Commission as an NRSRO. Kroll Bond Rating Agency Europe Limited is registered as a CRA with the European Securities and Markets Authority. Kroll Bond Rating Agency UK Limited is registered as a CRA with the UK Financial Conduct Authority. In addition, KBRA is designated as a Designated Rating Organization (DRO) by the Ontario Securities Commission for issuers of asset-backed securities to file a short form prospectus or shelf prospectus. KBRA is also recognized as a Qualified Rating Agency by Taiwan's Financial Supervisory Commission and is recognized by the National Association of Insurance Commissioners as a Credit Rating Provider (CRP) in the U.S. Doc ID: 1009865
